Melodiol Global Health Limited

Bonus Issue of Options and Other Corporate Updates

Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) is pleased to announce a pro- rata non-renounceable bonus issue of options to eligible shareholders on the basis of one (1) option (“Bonus Option”) for every twenty (20) fully paid ordinary shares (“Shares”) held on the Record Date, with the Bonus Option to be issued for nil consideration (“Bonus Offer”). The record date for the Bonus Offer is anticipated to be in early November 2023 (“Record Date”).


The purpose of the Bonus Offer is to recognise the support and loyalty the Company has received from its shareholders to date, especially in the backdrop of challenging macro market conditions.

The Bonus Offer is being made to all shareholders of the Company named on its register of members at the Record Date, whose registered address is in Australia, New Zealand, or any other jurisdictions to whom the Company decides to make the Bonus Offer (“Eligible Shareholders”).

The Bonus Options will be exercisable at $0.01 on or before 5:00pm (WST) on the date that is five years from the date of issue. The Company will seek official quotation of the Bonus Options on the ASX.

Based on the number of Shares on issue at the date of this announcement, a total of 160,564,889 Bonus Options will be issued pursuant to the Bonus Offer. For the purpose of calculating each Eligible Shareholder’s entitlement, fractional entitlements will be rounded down to the nearest whole number.

Full details of the Bonus Offer will be set out in a prospectus to be lodged by the Company on the ASX in early November 2023.

Other Corporate Updates

May Placement Update

Additionally, the Company provides the following update in respect of the placement undertaken in May 2023 (refer to ASX announcement dated 19 May 2023). The Company advises that one participant, who committed to providing $350,900 has yet to provide funds to the Company. The Company has persistently attempted to enforce that the investor comply with their obligations, however given the length of time that has passed, the Company now considers that it is unlikely to receive this commitment and therefore updates the market as such.


Click here for the full ASX Release

This article includes content from Melodiol Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

ME1:AU
Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Melodiol Global Health

Melodiol Global Health


Keep reading...Show less

Cronos Group Announces Expansion of GrowCo to Fuel Global Growth

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, announced an expansion of Cronos Growing Company ("GrowCo"). GrowCo is a leading cannabis cultivation company that Cronos owns 50% of. The investment will be funded by an additional credit facility provided by Cronos and is intended to assist GrowCo's expansion of its purpose-built cannabis facility to address the increased global market demand for high-quality cannabis flower.

Key Highlights of the Investment:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cannabis plant.

What Would US Cannabis Rescheduling Mean for Stocks and Investors?

The US Drug Enforcement Administration (DEA) has initiated proceedings to reclassify cannabis from a Schedule I substance to a Schedule III substance, marking a significant step towards cannabis reform in the country.

After months of deliberation, the Associated Press reported on April 30 that the DEA would move to reclassify cannabis from Schedule I, a category it currently shares with heroin and methamphetamines, to Schedule III, which is reserved for substances with low potential for dependence and accepted medical use.

The move from the DEA comes almost a year after the Department of Health and Human Services (HHS) suggested that cannabis be reclassified on August 29, 2023. In December 2023, the DEA sent a letter to Congress in which it indicated its intent to review the evidence provided by the HHS. This was followed by months of evaluation and consideration by the DEA, as well as discussions and advocacy for cannabis reform by lawmakers and other stakeholders.

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: US Moves to Reschedule Cannabis, Tilray Brands Seeks US Acquisitions

May saw officials in the Drug Enforcement Administration make the first moves toward cannabis rescheduling.

As anticipation builds, companies are beginning to better position themselves for changing market dynamics, and one Canadian cannabis company is anticipating major acquisition deals to come out of the US.

Meanwhile, a major player in the US market narrowly avoided consequences related to their Nasdaq listing after an expected merger agreement was terminated, and a once luxury cannabis brand out of California became officially delisted after months of financial uncertainty. Keep reading to discover more about these industry-shaping events.

Keep reading...Show less

Trulieve Announces Opening of 200th Dispensary

New Location in Brooksville, Florida opens today with grand opening celebration on June 14 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Brooksville, Florida marking the Company's 200 th dispensary in the United States .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Litigation Settlement and Acquisition of Ohio Assets

Trulieve adds two medical dispensaries in Beavercreek and Columbus to Ohio footprint

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has reached an agreement resolving the active litigation.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Speak at Bernstein's 40th Annual Strategic Decisions Conference

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at Bernstein's 40th Annual Strategic Decisions Conference on Thursday, May 30, 2024, at 2:30PM ET.

A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×